MX2018016331A - Formas cristalinas de compuesto de triazolopirimidina. - Google Patents

Formas cristalinas de compuesto de triazolopirimidina.

Info

Publication number
MX2018016331A
MX2018016331A MX2018016331A MX2018016331A MX2018016331A MX 2018016331 A MX2018016331 A MX 2018016331A MX 2018016331 A MX2018016331 A MX 2018016331A MX 2018016331 A MX2018016331 A MX 2018016331A MX 2018016331 A MX2018016331 A MX 2018016331A
Authority
MX
Mexico
Prior art keywords
crystalline forms
triazolopyrimidine compound
triazolopyrimidine
compound
prc2
Prior art date
Application number
MX2018016331A
Other languages
English (en)
Inventor
Mao Liang
Zhang Lijun
Liu Bo
Huang Ying
Wang Long
Murlidhar Waykole Liladhar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2018016331A publication Critical patent/MX2018016331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan formas cristalinas de un compuesto de triazolopirimidina, que son útiles para el tratamiento de una enfermedad o trastorno mediado por PRC2.
MX2018016331A 2016-06-20 2017-06-19 Formas cristalinas de compuesto de triazolopirimidina. MX2018016331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016086350 2016-06-20
PCT/CN2017/089003 WO2017219948A1 (en) 2016-06-20 2017-06-19 Crystalline forms of triazolopyrimidine compound

Publications (1)

Publication Number Publication Date
MX2018016331A true MX2018016331A (es) 2019-05-20

Family

ID=60783815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016331A MX2018016331A (es) 2016-06-20 2017-06-19 Formas cristalinas de compuesto de triazolopirimidina.

Country Status (14)

Country Link
US (2) US11091489B2 (es)
EP (1) EP3472168B1 (es)
JP (1) JP7042812B2 (es)
KR (1) KR102519922B1 (es)
CN (1) CN109563100B (es)
AU (1) AU2017282871B2 (es)
BR (1) BR112018076443A2 (es)
CA (1) CA3027246A1 (es)
CL (2) CL2018003734A1 (es)
IL (1) IL263429B (es)
MX (1) MX2018016331A (es)
RU (1) RU2754856C2 (es)
SA (1) SA518400704B1 (es)
WO (1) WO2017219948A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
ES2928856T3 (es) 2015-11-19 2022-11-23 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
UA126113C2 (uk) 2015-12-22 2022-08-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017222976A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019012957A2 (pt) 2016-12-22 2019-11-26 Incyte Corp derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
PT3746446T (pt) * 2018-01-31 2022-07-18 Mirati Therapeutics Inc Inibidores de prc2
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
SI3774791T1 (sl) 2018-03-30 2023-04-28 Incyte Corporation Heterociklične spojine kot imunomodulatorji
DK3790877T3 (da) 2018-05-11 2023-04-24 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AU2020332462B2 (en) * 2019-08-22 2023-08-17 Shanghai Blueray Biopharma Co., Ltd. Azaheteroaryl compound and application thereof
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
CN110796297B (zh) * 2019-10-21 2020-11-10 浙江大学 一种基于平衡度方差和可靠度的电力系统结构优化方法
KR20220097449A (ko) * 2019-11-01 2022-07-07 상하이테크 유니버시티 Eed 억제제, 및 이의 제조방법 및 용도
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
CN115916209A (zh) * 2020-05-28 2023-04-04 诺华股份有限公司 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
CN114426541B (zh) * 2020-10-29 2023-06-30 成都先导药物开发股份有限公司 氮杂芳基化合物及其用途
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
JP2023548859A (ja) 2020-11-06 2023-11-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス
WO2022105852A1 (zh) 2020-11-20 2022-05-27 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA04008722A (es) 2002-03-08 2005-07-13 Eisai Co Ltd Compuestos macrociclicos utiles como farmaceuticos.
HUE025767T2 (en) 2002-03-13 2016-05-30 Array Biopharma Inc N3-alkylated benzimidazole derivatives as MEK inhibitors
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
PL1912636T3 (pl) 2005-07-21 2015-02-27 Ardea Biosciences Inc N-(aryloamino)sulfonamidowe inhibitory mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN102887900B (zh) * 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
US8247397B2 (en) 2007-09-12 2012-08-21 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
KR20100133385A (ko) 2008-02-26 2010-12-21 노파르티스 아게 Ｃｘｃｒ2의 억제제로서의 헤테로시클릭 화합물
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
AR075344A1 (es) 2009-01-30 2011-03-23 Takeda Pharmaceutical Derivados heterociclicos nitrogenados fusionados, medicamentos que los contienen y uso de los mismos en el tratamiento de enfermedades cardiacas, renales y metabolicas, entre otras
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
KR102373074B1 (ko) 2010-09-10 2022-03-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
WO2013039988A1 (en) 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
KR102587175B1 (ko) 2012-03-12 2023-10-06 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
SG11201506077XA (en) 2013-02-11 2015-08-28 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
RU2015139054A (ru) 2013-03-14 2017-04-19 Дженентек, Инк. Способы лечения рака и профилактики лекарственной резистентности рака
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
HUE042290T2 (hu) 2014-11-14 2019-06-28 Basf Se Benzil-propargil-éterek, mint nitrifikáció inhibitorok
ES2668688T3 (es) 2014-12-16 2018-05-21 Omya International Ag Carbonato de calcio para protección vegetal
SG11201703880VA (en) * 2014-12-23 2017-07-28 Novartis Ag Triazolopyrimidine compounds and uses thereof
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
US20190211022A1 (en) 2019-07-11
EP3472168A4 (en) 2019-12-11
CL2018003734A1 (es) 2019-02-15
RU2754856C2 (ru) 2021-09-08
RU2019101220A3 (es) 2020-10-28
JP2019522051A (ja) 2019-08-08
EP3472168A1 (en) 2019-04-24
CA3027246A1 (en) 2017-12-28
CL2020002277A1 (es) 2021-02-12
SA518400704B1 (ar) 2022-11-03
IL263429A (en) 2018-12-31
US11091489B2 (en) 2021-08-17
KR20190020753A (ko) 2019-03-04
EP3472168B1 (en) 2024-01-10
BR112018076443A2 (pt) 2019-04-09
US20210340152A1 (en) 2021-11-04
AU2017282871A1 (en) 2018-12-20
CN109563100A (zh) 2019-04-02
CN109563100B (zh) 2021-08-27
IL263429B (en) 2022-08-01
WO2017219948A1 (en) 2017-12-28
JP7042812B2 (ja) 2022-03-28
US11548897B2 (en) 2023-01-10
KR102519922B1 (ko) 2023-04-11
AU2017282871B2 (en) 2020-03-05
RU2019101220A (ru) 2020-07-21

Similar Documents

Publication Publication Date Title
MX2018016331A (es) Formas cristalinas de compuesto de triazolopirimidina.
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
PH12017501016B1 (en) Triazolopyrimidine compounds and uses thereof
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
GR20140100479A (el) Συνθεση λιραγλουτιδης
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2017016041A (es) Metodos para usar activadores de piruvato cinasa.
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
MY195000A (en) Method for the treatment of neurological disease
MX2020007742A (es) Procesos para preparar fluorocetolidos.
IL274014B (en) The process of producing herbicidal pyridazinone compounds
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2016015298A (es) Inhibidores de nampt y metodos.
PH12017500492A1 (en) Crystalline bace inhibitors
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
MX2017003728A (es) Sistema mejorador de sabor.
IN2014MU00072A (es)
MX2018007638A (es) Proceso mejorado para preparar crotonilaminopiridinas.